Videos

A thrombosis expert details cerebral venous thrombosis, the side effect reported in a half-dozen women administered the Johnson & Johnson vaccine.

Patrick McGann, MD, MS, reviews the role of hydroxyurea in sickle cell disease, touching on the mechanism of action and expected outcomes.

Clinicians dive into the impact of sickle cell on quality of life and symptom management

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, review how early long-acting injectables should be started in patients with schizophrenia.

Henry Nasrallah, MD, and Rahn Bailey, MD, DFAPA, discuss how to switch a patient from oral to a long-acting injectable antipsychotic from their own experience.

Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy. 

Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.

Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.

Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.

Patient factors considered when prescribing treatment options for the management of atopic dermatitis.

A discussion on the safety and efficacy of angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, for the treatment of heart failure.

Experts in cardiology provide a brief history on treatments used for heart failure including ACE (angiotensin converting enzyme) inhibitors and beta blockers.

Abdullah Kutlar, MD, reviews the guideline recommendations for screening and monitoring of anemia-related sickle cell disease manifestations.

Key opinion leaders give insight on the presentation of sickle cell disease, also highlighting acute vs chronic complications of the disease.

Joe Avelino, RN, BSN, MHSA, CPHQ, reviews the benefits of using long-acting injectables (LAIs) and Henry Nasrallah, MD, reviews his techniques for getting patients to accept LAIs and continue with them. 

Henry Nasrallah, MD, discusses patient factors that lead to long-acting injectable treatment in patients with schizophrenia.  

A dermatologist discusses alternative and complementary options for the treatment of atopic dermatitis.

Experts address barriers to overcome regarding naloxone prescribing, dispensing, and utilization that they have seen in the community.

Multidisciplinary expert panel share perspectives on stigmatization and normalization of the conversation about naloxone between clinicians and patients.

A dermatologist gives a broad overview of key considerations when determining a treatment course for pediatric patients.

Manesh Patel, MD, briefly addresses the mechanism of action of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

Dean Karalis, MD, provides his perspective on intensive LDL lowering in patients with risk for high cholesterol and related disorders.

Reviewing the importance of newer models of collaboration between specialty and primary care for atopic dermatitis and educating patients and caregivers for disease management.

Lawrence F. Eichenfield, MD; Jeffrey M. Bienstock, MD, FAAP; Peter A. Lio, MD; and Elizabeth A. Swanson, MD, discuss the importance of an integrative approach to care for the management of atopic dermatitis.

New data show reduced risk of mortality, and clinical savings upward of $100,000, are linked to sometimes inaccessible substance use disorder therapies.

The pandemic forced practices to consider more virtual screening and care. A dermatologist shares perspective on what's been working as telemedicine practice.

Using the ACC Expert Consensus Decision Pathway documents for the optimization of heart failure treatment and managing the increasing complexity of the disease.

A look into the role of heart failure treatment in health care and the overall provision of optimal medical therapy.